Literature DB >> 2073908

HDL metabolism and its role in lipid transport.

N E Miller1.   

Abstract

High density lipoprotein (HDL) plays an essential role in plasma lipid transport. It provides a reservoir of C apolipoproteins, which are required for the metabolism of chylomicrons and very low density lipoproteins (VLDL), and acts as a scavenger of surplus unesterified cholesterol from these lipoproteins. HDL is also the major vehicle for the transport of cholesterol from peripheral cells to the liver for excretion and catabolism. This process, known as reverse cholesterol transport, occurs in three stages: extravascular, intravascular, and intrahepatic. In the extravascular phase, unesterified cholesterol is removed from cell membranes by small apoprotein (apo) A-I-containing particles in interstitial fluid. This may be facilitated by binding of the particles to cell surface receptors that recognize apo A-I. After entry into the blood via peripheral lymph, cholesterol in these and other HDL particles is esterified by the associated enzyme, lecithin: cholesterol acyltransferase. Some of the cholesteryl esters that are formed are transferred to chylomicrons and VLDL by a transfer protein. Others are incorporated into the core of HDL particles, which then increase in size and decrease in density. Ultimately these HDL particles associate with apo E, which is synthesized and secreted by some peripheral tissues at a rate regulated by their cell cholesterol content. Removal of cholesteryl esters from the circulation occurs in the liver by receptor-mediated uptake of HDL--with apo E, chylomicron remnants, VLDL remnants, and low density lipoprotein--and by direct transfer of cholesteryl esters from HDL particles into liver cells. Cholesterol is eliminated by hepatocytes by secretion into the bile, and by conversion to primary bile ducts.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2073908     DOI: 10.1093/eurheartj/11.suppl_h.1

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  6 in total

1.  Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men.

Authors:  B Lamarche; K D Uffelman; A Carpentier; J S Cohn; G Steiner; P H Barrett; G F Lewis
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

2.  Remodeling and shuttling. Mechanisms for the synergistic effects between different acceptor particles in the mobilization of cellular cholesterol.

Authors:  W V Rodrigueza; K J Williams; G H Rothblat; M C Phillips
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-02       Impact factor: 8.311

Review 3.  High-Density Lipoprotein Function and Dysfunction in Health and Disease.

Authors:  Scott T Chiesa; Marietta Charakida
Journal:  Cardiovasc Drugs Ther       Date:  2019-04       Impact factor: 3.727

4.  Human ApoA-I Overexpression Enhances Macrophage-Specific Reverse Cholesterol Transport but Fails to Prevent Inherited Diabesity in Mice.

Authors:  Karen Alejandra Méndez-Lara; Núria Farré; David Santos; Andrea Rivas-Urbina; Jari Metso; José Luis Sánchez-Quesada; Vicenta Llorente-Cortes; Teresa L Errico; Enrique Lerma; Matti Jauhiainen; Jesús M Martín-Campos; Núria Alonso; Joan Carles Escolà-Gil; Francisco Blanco-Vaca; Josep Julve
Journal:  Int J Mol Sci       Date:  2019-02-02       Impact factor: 5.923

5.  The role of exercise training on lipoprotein profiles in adolescent males.

Authors:  Majid S Koozehchian; Farzad Nazem; Richard B Kreider; William J Roberts; Thomas M Best; Yi Rong; Li Zuo
Journal:  Lipids Health Dis       Date:  2014-06-09       Impact factor: 3.876

Review 6.  Regulation of ATP binding cassette transporter A1 (ABCA1) expression: cholesterol-dependent and - independent signaling pathways with relevance to inflammatory lung disease.

Authors:  Patrick He; Ingrid C Gelissen; Alaina J Ammit
Journal:  Respir Res       Date:  2020-09-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.